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OBJECTIVE—Introduction of genes targeted in 129/Sv embry-
onic stem (ES) cells into NOD mice brings about linked genes
that may modulate type 1 diabetes. Our objective was to identify
129S1/SvJ non-MHC regions contributing type 1 diabetes resis-
tance or susceptibility in backcross to NOD/LtJ.
RESEARCH DESIGN AND METHODS—After congenic trans-
fer of the NOD H2
g7 haplotype onto 129S1/Sv, 310 females were
produced by NOD  (NOD  129.H2
g7)F1 backcross (N2). A
genome scan for quantitative trait locus (QTL) affecting clinical
diabetes, age of diabetes onset, and insulitis severity was per-
formed using subphenotype characteristics to improve power
and resolution for detection of diabetes susceptibility loci.
RESULTS—Thirty-six of 310 (11.6%) N2 females developed type
1 diabetes between 14 and 40 weeks. Signiﬁcant evidence of
linkage for only a single previously reported Idd complex locus
(Idd10/17/18, chromosome [Chr] 3) was indicated for clinical
diabetes. The quantitative traits of insulitis either alone or
combined with age at type 1 diabetes onset were signiﬁcantly
linked to known Idd regions on Chr 1 (Idd5 region), Chr 4 (Idd9
region), Chr 8 (Idd22), Chr 11 (Idd4.3), and proximal Chr 17
(Idd16 region). Signiﬁcant 129S1/Sv resistance contributions
were identiﬁed on Chr 1, 15 (two loci), and 19, with suggestive
evidence for additional novel 129/Sv resistance QTL on Chr 5 and
17 and susceptibility on Chr 2.
CONCLUSIONS—The 129S1/SvJ genome harbors collections of
both known and potentially novel non-MHC Idd loci. Investiga-
tors targeting 129/Sv genes mapping within chromosomal regions
reported herein or elsewhere in the genome need to exclude
potential contributions from linked Idd loci by generating a
NOD.129 control strain expressing the nontargeted allele.
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G
ene targeting in embryonic stem (ES) cells
represents a powerful molecular genetic tool
for interrogating the role of speciﬁc genes in
the development of type 1 diabetes in the NOD
mouse. Although pure ES cell lines have been generated,
most show no to negligible germ-line competency (1–4).
Thus, almost all targeted mutations reported have been
generated in fully germ-line competent ES cell lines de-
rived from various 129/Sv substrains. This presents a
problem. Whenever a gene is targeted in 129/Sv ES cells
and then introduced into the NOD mouse genetic back-
ground, variable numbers of linked genes are inadver-
tently introduced as well. In the Type 1 Diabetes Resource
at The Jackson Laboratory (http://type1diabetes.jax.org/
index.html), almost one-third of the NOD stocks in this
repository represent congenics carrying introduced 129/Sv
genome proximal and distal to the targeted allele. When an
alteration in type 1 diabetes incidence is observed in such
a congenic stock, the formal possibility exists that some
or all of the effect is contributed not by the loss-of-function
allele but, rather, by a linked gene or genes. Previous
outcrosses between NOD and stocks of C57BL/10J or
NON/Lt mice for which genomes were previously “condi-
tioned” by prior congenic introduction of the NOD’s
diabetogenic H2
g7 MHC haplotype have permitted identi-
ﬁcation of major non-MHC Idd diabetes modiﬁer loci from
these resistant strains (5). Despite the large numbers of
NOD stocks congenic for 129/Sv genomic segments, no
comparable search for 129/Sv-contributed non-MHC Idd
loci has been undertaken. Our objective was to identify
such chromosomal regions derived from 129S1/SvJ, a
substrain for which ES cells are commonly used for gene
targeting, that contribute type 1 diabetes resistance or
susceptibility in a dominant or additive fashion in back-
cross to NOD/LtJ.
RESEARCH DESIGN AND METHODS
Pedigreed NOD/ShiLtJ and 129S1/SvImJ mice were obtained from The Jack-
son Laboratory. All mice were maintained at high speciﬁc pathogen-free
conditions on a 6% fat diet (irradiated Lab Diet 5LG4; PMI, Brentwood, MO)
and acidiﬁed water. In outcrosses of NOD to MHC-disparate strains, homozy-
gosity for the diabetogenic NOD H2
g7 haplotype is required for type 1 diabetes
development at sufﬁciently high prevalence to permit non-MHC linkage
detection. Accordingly, we ﬁrst developed a “speed congenic” chromosome
(Chr) 17 stock of 129S1/Sv mice expressing H2
g7. After NOD  129S1/SvJ
outcross, six cycles of backcrossing to 129S1/Sv were performed with
selection for MHC heterozygosity. Males exhibiting maximum 129S1/Sv ho-
mozygosity at 142 polymorphic non-MHC SNP markers (supplementary Table
A1, available in an online-only appendix at http://diabetes.diabetesjournals.
org/cgi/content/full/dc09-0120/DC1) were selected as breeders. At N7, the Chr
17 congenic interval spanned NOD markers at D17Mit175 (32 Mb) proximal
and D17Mit34 (34.8 Mb) distal, with all non-MHC markers conﬁrmed as
homozygous. This stock is currently at N10 and designated 129.NOD-
(D17Mit175-H2)/J. MHC heterozygous sib matings generated 129.H2
g7 ho-
mozygous males for outcross to NOD. Small cohorts of (NOD  129.H2
g7)F 1
and F2 mice were aged to 28 and 40 weeks, respectively. The complete
absence of type 1 diabetes and insulitis in F1 mice and the absence of type 1
diabetes and rarity of insulitis in F2 mice necessitated a backcross strategy.
A total of 310 females were produced by NOD  (NOD  129.H2
g7)F1
backcross (N2) and quantitative trait locus (QTL) analysis completed for the
phenotypes of clinical diabetes, age of diabetes onset, and insulitis severity/
extent in nondiabetic animals aged to 40 weeks. Clinical diabetes was
assessed by two strongly positive glycosuria readings (Diastix, Bayer) 1 week
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1700 DIABETES, VOL. 58, JULY 2009apart. Insulitis severity/extent in nondiabetic females surviving to 40 weeks
was assessed semiquantitatively in three nonoverlapping sections of aldehyde
fuchsin/hematoxylin-eosin–stained pancreata. A scale of 0 (no insulitis, nor-
mal -cell mass) to 4 (only small islet residua with no surviving aldehyde
fuchsin staining -cells, a score characterizing all clinically diabetic females)
in 0.5 increments was used. We have previously shown that the information
content of another quantiﬁable phenotype limited to the diabetic probands,
their age at diabetes onset, could be combined with the insulitis severity/
extent phenotypic score to increase the power of QTL analysis (6). Week of
diabetes onset was converted to a similar 0–4 scale covering 27 weekly
sampling intervals from 14 weeks (ﬁrst diabetic mouse) to 40 weeks (last
diabetic mouse), with each interval weighted at 0.148 units. Thus, earliest
onset time (14 weeks) received maximum score (27  0.148  4.0), whereas
latest onset time (40 weeks) received only one 0.148 increment. When
diabetes onset score is combined with the diabetic 4.0 insulitis score, the two
variables provided a continuous range of values between 4.148 and 8,
reﬂecting diabetes progression over time.
DNA from tail and spleen was typed using 146 single nucleotide polymor-
phisms (SNPs) giving 20–30 Mb coverage. An additional 9–24 SNPs were
added within each QTL region to increase coverage to 2–5 Mb, for a ﬁnal total
of 313 SNPs genotyped (supplementary Table A2). All SNP typing was
performed by KBioscience (Hoddesdon, U.K.). A three-step QTL analysis was
performed in R/qtl (7) to search for main effects and pair-wise epistatic
interactions followed by ﬁtting a multiple regression model, as described in
detail previously (6). Those QTLs meeting or exceeding a 95% genome-wide
adjusted threshold assessed by 1,000 permutation analysis (logarithm of odds
[LOD] 2.8) were called signiﬁcant; those meeting or exceeding a 37%
genome-wide adjusted threshold (LOD 1.8) were called suggestive linkages.
Then, simultaneous genome scans for all pairs of markers were implemented
to detect epistatic interactions by ﬁtting a two-way ANOVA model with an
interaction item as previously described (6). An LOD score contrasting the full
model to a null model (with no genomic effects) is computed, and genome-
wide signiﬁcance is established by permutation analysis. A secondary test for
the signiﬁcance of the interaction term is computed only for those pairs that
pass the genome-wide screening. A stringent nominal signiﬁcance level (0.001)
is used for interaction test, and only those locus pairs passing both tests are
deemed to be interacting. Finally, all the detected main effect and interacting
QTLs were used to ﬁt multiple regression models. The ratio of the adjusted
(type III) sums of square for each marker or marker pair to the total sums of
squares is the percentage of variance explained.
RESULTS AND DISCUSSION
The raw data for this backcross have been deposited
online at http://phenome.jax.org/pub-cgi/phenome/mpdcgi?
rtnprojects/details&symQTL-Leiter1. Of the 310 N2 fe-
males aged to 40 weeks, 36 (11.6%) developed clinical
diabetes between 14 and 40 weeks of age, with variable
insulitis prevalent in females remaining diabetes free out
to 40 weeks. For this complex dichotomous trait, sugges-
tive evidence for linkage at two Idd regions previously
identiﬁed in outcross with C57BL/10J was found (Fig. 1A).
These included a peak marker at 100 Mb falling within the
Idd10/17/18 complex on Chr 3 (LOD  2.5) and a peak
marker at 142 Mb within the Idd9 complex on Chr 4
(LOD  2.4). A third suggestive 129/Sv resistance linkage
was identiﬁed on Chr 17 (Fig. 1A), immediately distal to
the NOD congenic segment. This linkage falls within the
Idd16 region identiﬁed in outcross with the NOD-related
ALR/Lt and CTS/Shi strains (8).
Quantitative subphenotypes of a binary disease trait can
improve power for mapping common genetic determi-
nants (9). Indeed, of the two quantitative traits analyzed,
insulitis score alone or combined with age at diabetes
onset (designated “combination trait”), the latter was
more robust for identiﬁcation of signiﬁcant and suggestive
QTL (Fig. 1B and C and summarized in Table 1). On Chr 1,
signiﬁcant evidence for linkage was found at the more
distal end (Idd5.4 region) of the previously described Idd5
complex for both traits (10). Genetic complexity across
this region was indicated by three 129-derived linkage
peaks at 85, 105, and 121 Mb. Suggestive evidence for a
novel 129S1/Sv-derived susceptibility Idd region on Chr 2
clearly proximal to the previously described Idd13 region
(11) was obtained using the combination trait. This QTL at
77 Mb is near loci encoding two candidate autoantigens:
IGRP (69 Mb) and GAD65 (70.4 Mb). The combination
trait, but not insulitis alone, showed suggestive linkage at
103.6 Mb on Chr 3. None of the phenotypes screened
showed linkage to the Idd3/Il2 region sited more proxi-
mally on Chr 3, an expected absence, since this region is
shared (identical by descent) between the two strains (12).
On Chr 4, both quantitative measures showed signiﬁcant
linkage of markers within the Idd9.2 region at 146 Mb,
with the combination trait also showing signiﬁcant linkage
to a marker at 126 Mb (Idd9.1?). A 129S1/Sv marker at 31
Mb on Chr 5 just missed the 1.8 LOD cutoff for suggestive
linkage to the combination trait. The combination trait
showed signiﬁcant linkage with a marker on Chr 8 over-
lapping the Idd22 resistance region previously described
in outcross with the ALR/Lt strain (13). Both traits showed
signiﬁcant linkage in the Idd4.2 region on Chr 11 as well as
to a more proximal region (Idd4.3), where C57L resistance
was reported (14). This ﬁnding, coupled with the absence
of any linkage for the trait of clinical diabetes, might
indicate that 129S1/Sv alleles at these loci were primarily
involved in retarding leukocyte inﬁltration rather than
affecting rates at which they killed -cells. Genome scan
for both subphenotypes identiﬁed two novel 129S1/Sv-
derived resistance QTL on Chr 15, with peaks at 31 and 55
Mb. On Chr 17, only the combination trait allowed identi-
ﬁcation of a signiﬁcant QTL at 24 Mb, sited above the
congenic MHC region whose upper boundary was marked
by the NOD allele at D17Mit175 at 32 Mb. A C57BL/6J-
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FIG. 1. Genome-wide scan for main effects. A: clinical diabetes. B:
combination trait combining insulitis score plus age of diabetes onset.
C: insulitis only in nondiabetic survivors to 40 weeks of age. Upper line
shows signiﬁcance at LOD >2.8; lower line shows suggestive linkage at
LOD >1.8.
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“Idd16” (15). A novel 129S1/Sv resistance locus was iden-
tiﬁed at 50 Mb on Chr 19 for both insulitis alone and the
combination trait. Interestingly, an NOD stock congenic for a
targeted mutation in the closely linked 129S2/Sv Ins1 gene
(52.3 Mb) exhibited a markedly suppressed diabetes inci-
dence (16). Although the protection was attributed to loss of
preproinsulin 1 itself because a control congenic carrying the
wild-type 129S1/Sv allele did not protect (16), importation of
this stock to the Type 1 Diabetes Resource at The Jack-
son Laboratory revealed a markedly attenuated type 1 diabe-
tes onset in females and almost complete suppression
in males (see http://type1diabetes.jax.org/incidence_studies/
005352.html). Hence, an additional 129S1/Sv passenger gene
near Ins1 or an expression variant of the Ins1 gene itself may
also contribute to the resistance observed. We propose that
this 129/Sv-derived resistance locus observed both by segre-
gation and congenic analyses provisionally be designated
Idd28.
Genome-wide two-locus scans for interactions affecting
insulitis alone did not detect any signiﬁcant interaction.
However, for the combination trait, a signiﬁcant two-locus
interaction between Chr 15 (at 55.2 Mb) and Chr 17 (at
53.9Mb) was detected (Fig. 2). Epistasis was indicated by
an LOD score of 7.56 (threshold is 7.0 based on permuta-
tion tests) from the full model and an LOD score of 3.90
(threshold  3.0) by contrasting the full model with one of
the two single QTL models (7). We then included all the
main effect QTLs and this interaction to ﬁt a multiple
regression model, and the interaction remained signiﬁcant.
Interestingly, whereas a suggestive 129S1/Sv resistance
QTL on Chr 17 was detected for clinical diabetes at 41 Mb
and for the combination trait at 24 Mb, a distinct Chr 17
locus at 54 Mb showed signiﬁcant interaction with the Chr
15 QTL. This more distal Chr 17 interactive QTL is novel,
since it mapped well below either of the two regions in the
literature referred to as “Idd16.”
Preliminary results from IngenuityPathway analysis in-
dicate nine pathways containing potentially interacting
proteins encoded within the two genetic regions, including
a direct protein-protein interaction between Ddef1 (Chr
15), a GTPase activator, and Ralbp1 (Chr 17), associated
with oxidative stress. Elucidation of such gene  gene
interactions in the control of type 1 diabetes is critical
toward understanding how an individual’s “genetic archi-
tecture” contributes to the development of a complex
disease. In summary, we have identiﬁed both known and
potentially novel Idd loci with additive or dominant effects
in the 129S1/Sv genome. These loci in aggregate only
account for 30% of the variance in the combination trait.
Because a backcross analysis can only detect additive or
dominant contributions, any recessive contributions
would be missed. One such recessive locus maps on Chr
10 near D10Mit87, close to the interferon  receptor gene
(17). Investigators targeting 129S1/Sv genes need to ex-
clude contributions from linked Idd loci mapping within
any of these chromosomal regions identiﬁed herein or that
remain to be identiﬁed elsewhere in the genome. This can
be accomplished by generating an additional NOD stock
carrying the wild-type allele in a congenic segment of
equal length.
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TABLE 1
Summary of genome-wide main effects scan for QTL controlling the combination trait (insulitis with age of diabetes onset) and
insulitis only
Chr Locus Peak at Mb* Susceptibility donor Combination trait % Variance Insulitis only % Variance
1 Idd5.4 region 85 NOD 3.62 3.69
1 Idd5.4 region 105 NOD 3.42 2.8 2.75 5.4
1 Idd5.4 region 121 NOD 3.41 3.14
2 Novel 77 129 2.17 2.8
3 Idd10/17/18 104 NOD 2.24 4.6
4 Idd9.1? 126 NOD 2.95
4.8 4 Idd9.2 146 NOD 4.28 2.76 4.7
5 Novel 31 NOD 1.72 1.3
8 Idd22 108 NOD 2.90 3.1
11 Idd4.3? 42 NOD 2.09
1.7
2.21
3.5 11 Idd4.2? 114 NOD 3.13 3.96
15 Novel 31 NOD 4.11
6.2
3.52
3.5 15 Novel 55 NOD 3.83 2.75
17 Idd16? 24 NOD 2.51 1.1
19 Novel 50 NOD 3.07 1.4 3.84 4.0
Signiﬁcant linkage requires LOD 2.8; suggestive linkage requires LOD 1.8. Percent variance contributed by each locus to the phenotype
is shown. *Megabase (Mb) positions from NCBI Ensembl Build 37.
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FIG. 2. Signiﬁcant interaction between an SNP marker on Chr 17
(17-050794277-N) and Chr 15 (15-055111506-N) for the combination
trait. The x-axis shows NOD homozygosity (N) or heterozygosity (H) at
Chr 17; the inset marks NOD homozygosity (F) or heterozygosity ()
at Chr 15. 129S1/Sv heterozygosity on Chr 17 abrogates NOD homozy-
gosity-conferred susceptibility on Chr 15.
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